We partner with the media to inform the public of the global human crisis.
February 20, 2019Indivior Announces Launch of SUBOXONE® (buprenorphine and naloxone) Sublingual Film Authorized Generic...
February 19, 2019The Lancet Publishes Phase 3 Results Demonstrating Efficacy, Safety and Tolerability of SUBLOCADE™ (Buprenorphine Extended-Release) Injection for Subcutaneous Use (CIII) in Patients with Moderate to Severe Opioid Use Disorder (OUD)...
February 14, 2019Presentation: Indivior FY 2018 Results Presentation (February 14) ...
February 14, 2019Indivior PLC FY 2018 Financial Results...
February 12, 2019Court of Appeals for the Federal Circuit Denies Motion to Stay Issuance of the Mandate...
Thursday, February 14th
November 6th, 2018
Thursday, November 1st
Global Media Contacts
EMEA, Australasia and China Financial Disclosure Reporting
Disclosure Of Payments, Donations & Joint Working
The Online Press Kit is designed to help media research our company for background information or follow-up stories. Please visit the links below to learn more.
About Indivior PLC – An overview of Indivior, including our worldwide locations and key products
Board of Directors – Biographies of Indivior’s Board
The Indivior PLC Pipeline – Information about the Indivior R&D efforts and progress of medicines in the pipeline